T3319 |
Scutellarein
|
529-53-3
|
99.7%
|
|
Scutellarein reduces inflammatory responses by inhibiting Src kinase activity.
|
T13194 |
CSF1R-IN-2
|
2271119-26-5
|
99.71%
|
|
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
|
T6321 |
Tofacitinib
|
477600-75-2
|
99.74%
|
|
Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.
|
T1667 |
Tandutinib
|
387867-13-2
|
99.74%
|
|
Tandutinib (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus CSF-1R an...
|
T1811 |
WH-4-023
|
837422-57-8
|
99.75%
|
|
WH-4-023 is a potent and orally active Lck/Src inhibitor. It also potently inhibits SIK.
|
T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T32613 |
LCB 03-0110 dihydrochloride
|
1962928-28-4
|
99.76%
|
|
LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2 fami...
|
T1835 |
Ibrutinib
|
936563-96-1
|
99.79%
|
|
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
|
T6886 |
MCB-613
|
1162656-22-5
|
99.8%
|
|
MCB-613 is an effective steroid receptor coactivator (SRC) stimulator.
|
T6920 |
ON123300
|
1357470-29-1
|
99.84%
|
|
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
|
T3593 |
Src Inhibitor 1
|
179248-59-0
|
99.84%
|
|
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.
|
T2640 |
Rebastinib
|
1020172-07-9
|
99.84%
|
|
DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT...
|
T3935 |
1-Naphthyl PP1
|
221243-82-9
|
99.85%
|
|
1-Naphthyl PP1 is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)
|
T4071 |
Repotrectinib
|
1802220-02-5
|
99.86%
|
|
TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
|
T2327 |
Pelitinib
|
257933-82-7
|
99.86%
|
|
Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
|
T6680 |
Staurosporine
|
62996-74-1
|
99.87%
|
|
Staurosporine is a potent PKC inhibitor for PKCα/γ/η (IC50: 2/5/4 nM), less potent to PKCε (73 nM), PKCδ (20 nM) and little action to PKCζ (1086 nM).
|
T1448L |
Dasatinib monohydrate
|
863127-77-9
|
99.89%
|
|
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoti...
|
T1448 |
Dasatinib
|
302962-49-8
|
99.89%
|
|
Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit, and c-KitD816V, respectively).
|
T2341 |
KW-2449
|
1000669-72-6
|
99.89%
|
|
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
|
T0152 |
Bosutinib
|
380843-75-4
|
99.9%
|
|
Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
|